Study guide
2.1 Brand vs Generic Mapping, USAN Stems, and Orange Book Therapeutic Equivalence
PTCB Technician Product Verification TPV
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Tech-Check-Tech Verification Fundamentals
1.1 About the PTCB TPV Certificate Exam 1.2 Tech-Check-Tech (TCT) Scope, Regulations, and Quality Assurance 1.3 Systematic Verification Protocol & Visual Inspection Steps
2 Chapter 2: Drug Name Verification & Brand/Generic Identification
2.1 Brand vs Generic Mapping, USAN Stems, and Orange Book Therapeutic Equivalence 2.2 Salt Forms and Active Ingredient Verification 2.3 Manufacturer-Specific Identification, Visual Cues, and Color Codes
3 Chapter 3: Auxiliary Labels, REMS & Controlled Substances
3.1 Auxiliary Warning Labels and Mandatory Patient Counseling Triggers 3.2 REMS Programs and Restricted Distribution Medications 3.3 Controlled Substance Scheduling, Refill Restrictions, and C-II Exact Counts
4 Chapter 4: Dosage Forms, Release Mechanisms & Administration Routes
4.1 Modified-Release Formulations (ER, XL, SR, DR, CR) and "Do Not Crush" Rules 4.2 Route of Administration Verification: Ophthalmic vs Otic, Oral vs Topical vs Transdermal 4.3 Specialized Delivery Systems: Inhalers (MDI/DPI), ODTs, Solutions vs Suspensions
5 Chapter 5: Strength Verification & Pharmaceutical Calculations
5.1 Unit Conversions (mcg, mg, g) and Preventing Leading/Trailing Zero Errors 5.2 Percentage Strengths, Ratio Strengths, and Liquid Concentrations (mg/mL) 5.3 Electrolyte Equivalents (mEq vs mg) and Combination Product Strength Verification
6 Chapter 6: High-Alert Medications & Safety Protocols
6.1 ISMP High-Alert Medications and Independent Double-Check Protocols 6.2 Insulin Formulations, Concentrations (U-100, U-500, U-200, U-300), and Pen/Vial Math 6.3 Concentrated Electrolytes, Opioids, Neuromuscular Blockers, and Oral Methotrexate
7 Chapter 7: Look-Alike / Sound-Alike (LASA) Medications
7.1 FDA and ISMP Tall-Man Lettering Principles 7.2 High-Risk Community/Ambulatory LASA Pairs 7.3 High-Risk Institutional/Hospital LASA Pairs & Packaging Traps
8 Chapter 8: Packaging, Expiration, Storage & Special Handling
8.1 Expiration Date Interpretation and Multi-Dose Vial Beyond-Use Dating (BUD) 8.2 Packaging Integrity, Moisture/Light Sensitivity, and FDA Recall Classes 8.3 Temperature Storage Ranges and Vaccine Cold Chain Integrity 8.4 USP <800> Hazardous Drug Identification and Handling Precautions
9 Chapter 9: NDC Conversion, Repackaging & Final Dispensing Checks
9.1 NDC 10-Digit to 11-Digit Conversion (5-4-2 Standardization) 9.2 Unit-Dose Repackaging Standards and USP <795> BUD Guidelines 9.3 Days Supply Calculations, Package Size Verification, and Final Label Matching
2.1 Brand vs Generic Mapping, USAN Stems, and Orange Book Therapeutic Equivalence
Key Takeaways Explain This Topic AI
The FDA Orange Book assigns two-letter therapeutic equivalence codes: 'A' codes (AA, AB, AN, AO, AP, AT) indicate therapeutic equivalence to the Reference Listed Drug (RLD), whereas 'B' codes signify actual or potential bioinequivalence requiring prescriber authorization to substitute.
Multi-source products with multiple reference standards carry three-character subcodes (e.g., AB1, AB2, AB3); a product rated AB2 (such as Synthroid) is interchangeable only with other AB2-rated levothyroxine products, not with AB3-rated products such as Levoxyl and Unithroid.
Pharmaceutical equivalents share identical active ingredients, dosage forms, strengths, and routes of administration, while pharmaceutical alternatives differ in salt form, ester, dosage form, or strength and cannot be automatically substituted under state generic substitution laws.
United States Adopted Name (USAN) stems identify pharmacological classes and mechanisms (e.g., -olol for beta-blockers, -pril for ACE inhibitors, -sartan for ARBs, -statin for HMG-CoA reductase inhibitors, -prazole for PPIs, -gliptin for DPP-4 inhibitors, -mab for monoclonal antibodies, -nib for kinase inhibitors).
Dispense as Written (DAW) codes dictate legal and insurance dispensing requirements: DAW 0 (generic allowed), DAW 1 (prescriber requested brand), and DAW 2 (patient requested brand) represent the most frequent verification checkpoints audited in pharmacy practice.
Last updated: August 2026
Brand vs. Generic Mapping, USAN Stems, and Orange Book Equivalence
Core Verification Rule: During final product verification, a pharmacy technician must confirm that any generic medication selected is legally, chemically, and therapeutically interchangeable with the prescribed brand product according to FDA standards and state pharmacy practice acts.
In modern pharmacy distribution, generic medications account for over 90% of all dispensed prescription volume. Verifying technicians must understand the regulatory mechanisms established by the Food and Drug Administration (FDA) that govern generic substitution, recognize standard pharmacological naming stems, and identify when generic substitution is restricted.
1. FDA Orange Book & Therapeutic Equivalence
The FDA publication formally titled Approved Drug Products with Therapeutic Equivalence Evaluations is universally known as the Orange Book . It serves as the definitive legal and clinical standard for determining whether a generic drug product can be safely substituted for a brand-name innovator drug (known as the Reference Listed Drug [RLD] ).
The Core Hierarchy of Equivalence
To understand Orange Book ratings, technicians must distinguish between three distinct regulatory tiers:
Pharmaceutical Equivalents: Drug products that contain the identical active ingredient(s) , in the identical dosage form , administered via the identical route , and possessing the identical strength or concentration . They may differ in shape, scoring configuration, release mechanisms, packaging, excipients (inactive ingredients), colors, flavorings, and expiration dating.
Pharmaceutical Alternatives: Drug products that contain the same active therapeutic moiety but differ in salt form, ester, complex, dosage form, or strength (e.g., tetracycline hydrochloride capsules vs. tetracycline phosphate complex capsules; quinidine sulfate tablets vs. quinidine gluconate tablets; metoprolol succinate ER vs. metoprolol tartrate IR). State laws prohibit automatic generic substitution of pharmaceutical alternatives.
Bioequivalent Drug Products: Pharmaceutical equivalents whose rate and extent of absorption (measured by Maximum Serum Concentration [ C m a x C_{max} C ma x ] and Area Under the Curve [ A U C AUC A U C ]) show no significant statistical difference from the RLD when administered at the same molar dose under similar experimental conditions (within the 80% to 125% 90% confidence interval).
Therapeutic Equivalents: Drug products that are both pharmaceutical equivalents AND bioequivalent . They can be expected to produce the same clinical effect and safety profile when administered to patients under conditions specified in the labeling. Therapeutic Equivalence = Pharmaceutical Equivalence + Proven Bioequivalence
2. Orange Book Rating Code System
The FDA uses a standardized two-to-three character coding system to categorize the therapeutic equivalence of multi-source prescription drug products.
Code Category First Letter Meaning Clinical / Legal Action
A-Rated A Therapeutically Equivalent to the Reference Listed Drug (RLD) Automatic substitution permitted under state generic substitution laws
B-Rated B NOT Therapeutically Equivalent ; actual or potential bioequivalence problems not resolved Automatic substitution prohibited; requires new prescription or prescriber authorization
Detailed 'A' Subcodes (Therapeutically Equivalent)
AB: Products meeting necessary bioequivalence requirements through in vivo and/or in vitro testing. This is the most common generic rating in community and hospital practice.
AA: Conventional dosage forms (tablets, capsules) with no bioequivalence issues or potential bioequivalence problems.
AN: Solutions and powders for aerosolization (e.g., nebulizer solutions).
AO: Injectable oil solutions.
AP: Injectable aqueous solutions and intravenous admixtures.
AT: Topical dermatological products (creams, ointments, lotions, gels) demonstrating bioequivalence.
Multi-Tier 'AB' Subcodes (AB1, AB2, AB3, AB4)
When multiple innovator brand-name formulations exist for the same active ingredient and strength (often due to historical patent developments or distinct pharmacokinetic matrices), the FDA assigns numerical subcodes ( AB1, AB2, AB3, AB4 ).
Important
Strict Subcode Alignment Rule: An AB1-rated generic is therapeutically equivalent ONLY to another AB1-rated product. An AB1 product is NOT interchangeable with an AB2, AB3, or AB4 product. Levothyroxine sodium tablets are the classic case, because several brands are each their own Reference Listed Drug. In the current Orange Book, Synthroid and Euthyrox are rated AB2 , while Levoxyl and Unithroid are rated AB3 — so Levoxyl and Unithroid are therapeutically equivalent to each other, but neither is equivalent to Synthroid. Always read the subcode off the current Orange Book rather than assuming, because these assignments have been revised as manufacturers completed additional bioequivalence studies.
Detailed 'B' Subcodes (Non-Therapeutically Equivalent)
BC: Extended-release dosage forms (tablets, capsules, injectables) with unresolved bioequivalence issues.
BD: Active ingredients and dosage forms with documented bioequivalence problems that have not been satisfied.
BE: Enteric-coated oral solid dosage forms with bioequivalence deficiencies.
BN: Aerosol-delivery drug products not demonstrating equivalence.
BP: Active ingredients with potential bioequivalence problems.
BR: Suppositories or enemas delivering systemic absorption with unresolved bioequivalence.
BS: Products having drug standard deficiencies.
BT: Topical products with bioequivalence issues.
BX: Specific drug products for which data are insufficient to determine therapeutic equivalence.
B*: Products requiring further FDA investigation to determine equivalence.
3. United States Adopted Name (USAN) Stems
The United States Adopted Names (USAN) Council establishes standardized generic nomenclature. Recognizing common stems allows technicians to quickly classify medications, identify their pharmacological category, anticipate therapeutic indications, and catch look-alike errors during product verification.
USAN Stem Pharmacological Class Clinical Mechanism Representative Generic & Brand Examples
-olol Beta-adrenergic blocker Antagonizes beta-1/beta-2 receptors; decreases heart rate and blood pressure Atenolol (Tenormin), Metoprolol (Lopressor/Toprol-XL), Carvedilol (Coreg)
-pril ACE inhibitor Inhibits angiotensin-converting enzyme; prevents conversion of Ang I to Ang II Lisinopril (Prinivil/Zestril), Enalapril (Vasotec), Ramipril (Altace)
-sartan Angiotensin II Receptor Blocker (ARB) Blocks AT1 receptors; induces vasodilation and aldosterone reduction Losartan (Cozaar), Valsartan (Diovan), Olmesartan (Benicar)
-statin HMG-CoA reductase inhibitor Inhibits rate-limiting cholesterol biosynthesis enzyme Atorvastatin (Lipitor), Rosuvastatin (Crestor), Simvastatin (Zocor)
-prazole Proton Pump Inhibitor (PPI) Irreversibly blocks H+/K+ ATPase enzyme system in gastric parietal cells Omeprazole (Prilosec), Pantoprazole (Protonix), Esomeprazole (Nexium)
-gliptin DPP-4 inhibitor Inhibits dipeptidyl peptidase-4; increases incretin hormone concentrations Sitagliptin (Januvia), Linagliptin (Tradjenta), Saxagliptin (Onglyza)
-mab Monoclonal antibody Targeted immunological protein binding specific cell surface antigens Adalimumab (Humira), Trastuzumab (Herceptin), Pembrolizumab (Keytruda)
-nib Kinase / Tyrosine kinase inhibitor Inhibits cellular signal transduction involved in oncology pathways Imatinib (Gleevec), Ibrutinib (Imbruvica), Erlotinib (Tarceva)
-flozin SGLT2 inhibitor Inhibits sodium-glucose co-transporter 2 in proximal renal tubules Empagliflozin (Jardiance), Dapagliflozin (Farxiga), Canagliflozin (Invokana)
-tidine H2 receptor antagonist Competitively blocks histamine H2 receptors on parietal cells Famotidine (Pepcid), Cimetidine (Tagamet), Nizatidine (Axid)
-cillin Penicillin antibiotic Inhibits bacterial cell wall peptidoglycan synthesis Amoxicillin (Amoxil), Ampicillin (Principen), Penicillin V Potassium (Veetids)
-floxacin Fluoroquinolone antibiotic Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV Ciprofloxacin (Cipro), Levofloxacin (Levaquin), Moxifloxacin (Avelox)
-afil Phosphodiesterase-5 (PDE-5) inhibitor Inhibits cGMP degradation; enhances smooth muscle relaxation and blood flow Sildenafil (Viagra/Revatio), Tadalafil (Cialis/Adcirca), Vardenafil (Levitra)
-triptan Serotonin 5-HT1B/1D agonist Constricts cranial vessels and inhibits pro-inflammatory neuropeptide release Sumatriptan (Imitrex), Rizatriptan (Maxalt), Zolmitriptan (Zomig)
-vir Antiviral agent Inhibits viral replication (reverse transcriptase, protease, or neuraminidase) Acyclovir (Zovirax), Valacyclovir (Valtrex), Oseltamivir (Tamiflu)
-dipine Dihydropyridine Calcium Channel Blocker Blocks L-type voltage-gated calcium channels in vascular smooth muscle Amlodipine (Norvasc), Nifedipine (Procardia/Adalat), Felodipine (Plendil)
-dronate Bisphosphonate Inhibits osteoclast-mediated bone resorption Alendronate (Fosamax), Ibandronate (Boniva), Risedronate (Actonel)
-terol Beta-2 adrenergic agonist Stimulates bronchial beta-2 receptors; causes bronchodilation Albuterol (ProAir/Ventolin), Salmeterol (Serevent), Formoterol (Foradil)
-glitazone Thiazolidinedione (TZD) Activates PPAR-gamma; enhances peripheral insulin sensitivity Pioglitazone (Actos), Rosiglitazone (Avandia)
-zosin Alpha-1 adrenergic blocker Blocks peripheral alpha-1 receptors; reduces vascular tone and relaxes prostate Doxazosin (Cardura), Prazosin (Minipress), Terazosin (Hytrin), Tamsulosin (Flomax)
4. Top 100 Brand-to-Generic Core Mapping Matrix
Technicians performing product verification must have instant recall of high-volume brand-to-generic mappings to catch mismatches between the prescribed hardcopy and the product dispensed.
- Therapeutic Category Brand Name Generic Name High-Yield Verification Notes
- Cardiovascular Lipitor Atorvastatin calcium HMG-CoA reductase inhibitor; lipid lowering
- Norvasc Amlodipine besylate Dihydropyridine CCB; peripheral edema monitoring
- Cozaar Losartan potassium ARB; check potassium salt form
- Prinivil / Zestril Lisinopril ACE inhibitor; dry cough / angioedema risk
- Toprol-XL Metoprolol succinate Extended-release beta-blocker; once-daily dosing
- Lopressor Metoprolol tartrate Immediate-release beta-blocker; twice-daily dosing
- Coreg Carvedilol Non-selective beta/alpha-1 blocker; take with food
- Lasix Furosemide Loop diuretic; sulfa moiety awareness
- Microzide Hydrochlorothiazide (HCTZ) Thiazide diuretic; photosensitivity warning
- Crestor Rosuvastatin calcium Potent statin; renal dose adjustment considerations
- Endocrine / Diabetes Glucophage Metformin hydrochloride Biguanide; renal function / lactic acidosis alert
- Synthroid Levothyroxine sodium NTI thyroid hormone; exact AB rating check required
- Januvia Sitagliptin phosphate DPP-4 inhibitor; pancreatitis warning
- Jardiance Empagliflozin SGLT2 inhibitor; UTI / euglycemic DKA monitoring
- Farxiga Dapagliflozin SGLT2 inhibitor; heart failure / CKD indications
- Ozempic / Rybelsus Semaglutide GLP-1 receptor agonist; refrigerated subcutaneous vs oral
- Actos Pioglitazone TZD; black box warning for heart failure (fluid retention)
- CNS / Psych / Neuro Zoloft Sertraline hydrochloride SSRI; depression/anxiety
- Lexapro Escitalopram oxalate SSRI; enantiopure formulation
- Prozac Fluoxetine hydrochloride SSRI; long half-life (norfluoxetine metabolite)
- Celexa Citalopram hydrobromide SSRI; QT-prolongation dose capping (max 40 mg/day)
- Cymbalta Duloxetine hydrochloride SNRI; neuropathic pain / fibromyalgia indication
- Effexor XR Venlafaxine hydrochloride SNRI; monitor blood pressure at higher doses
- Desyrel Trazodone hydrochloride SARI; hypnotic / sedative dosing at bedtime
- Xanax Alprazolam C-IV Benzodiazepine; rapid onset / high abuse liability
- Ativan Lorazepam C-IV Benzodiazepine; intermediate half-life
- Klonopin Clonazepam C-IV Benzodiazepine; long-acting anxiolytic/anticonvulsant
- Keppra Levetiracetam Anticonvulsant; behavioral / mood changes monitoring
- Neurontin Gabapentin GABA analog; neuropathic pain / postherpetic neuralgia
- Lyrica Pregabalin C-V Controlled substance; neuropathic pain
- Gastrointestinal Prilosec Omeprazole PPI; take 30-60 min prior to first meal
- Nexium Esomeprazole magnesium S-enantiomer PPI; delayed-release capsule/granules
- Protonix Pantoprazole sodium Delayed-release tablet; do not crush or split
- Pepcid Famotidine H2 blocker; renal dosage adjustment
- Zofran Ondansetron hydrochloride 5-HT3 antagonist; oral disintegrating tablet (ODT) vs tablet
Respiratory ProAir HFA / Ventolin HFA Albuterol sulfate Short-acting beta-2 agonist (SABA); check actuation counter
- Flovent HFA Fluticasone propionate Inhaled corticosteroid (ICS); rinse mouth after use
- Singulair Montelukast sodium Leukotriene receptor antagonist; black box neuropsychiatric
- Advair Diskus Fluticasone / Salmeterol ICS / LABA combination; DPI inhalation device
- Symbicort Budesonide / Formoterol ICS / LABA combination; MDI inhalation device
- Spiriva HandiHaler Tiotropium bromide Long-acting anticholinergic (LAMA); capsule for inhalation only
- Anti-Infective Amoxil Amoxicillin Aminopenicillin; reconstitutable suspension verification
- Augmentin Amoxicillin / Clavulanate Beta-lactamase inhibitor combo; clavulanate ratio check
- Zithromax Azithromycin Macrolide antibiotic; Z-Pak 250 mg vs Tri-Pak 500 mg
- Cipro Ciprofloxacin hydrochloride Fluoroquinolone; black box warning for tendonitis/rupture
- Levaquin Levofloxacin Fluoroquinolone; once-daily broad-spectrum dosing
Bactrim / Septra Sulfamethoxazole / Trimethoprim Sulfonamide combo; single strength (SS) vs double strength (DS)
- Keflex Cephalexin 1st generation cephalosporin; cross-reactivity with penicillin
- Diflucan Fluconazole Azole antifungal; CYP3A4 / CYP2C9 inhibitor interactions
- Analgesic / Anti-inflammatory Motrin / Advil Ibuprofen NSAID; GI bleed / renal impairment risk
- Aleve / Naprosyn Naproxen / Naproxen sodium NSAID; base vs sodium salt considerations
- Mobic Meloxicam NSAID; once-daily COX-2 preferential dosing
- Celebrex Celecoxib Selective COX-2 inhibitor; sulfa allergy cross-reactivity
- Ultram Tramadol hydrochloride C-IV Synthetic opioid agonist / SNRI; seizure risk
- Norco / Vicodin Hydrocodone / Acetaminophen C-II Opioid combo; max 325 mg APAP per dosage unit
- Percocet Oxycodone / Acetaminophen C-II Opioid combo; check APAP ceiling dose
- Anticoagulants Coumadin / Jantoven Warfarin sodium Vitamin K antagonist; NTI drug requiring INR monitoring
- Eliquis Apixaban Direct Factor Xa inhibitor; twice-daily fixed dosing
- Xarelto Rivaroxaban Direct Factor Xa inhibitor; 15/20 mg taken with evening meal
- Pradaxa Dabigatran etexilate Direct Thrombin inhibitor; keep in original desiccant bottle
- Plavix Clopidogrel bisulfate Antiplatelet P2Y12 inhibitor; CYP2C19 bioactivation
- 5. Narrow Therapeutic Index (NTI) Drugs
Narrow Therapeutic Index (NTI) medications (also referred to as narrow therapeutic ratio or critical-dose drugs) are defined as agents where there is a narrow margin between therapeutic efficacy and lethal or severe toxic manifestations . Therapeutic Index (TI) = Median Lethal Dose (LD50) / Median Effective Dose (ED50)
For NTI drugs, minor differences in formulation, bioavailability, or generic manufacturing can produce subtherapeutic treatment failure (e.g., organ rejection, seizures, stroke) or life-threatening toxicity (e.g., fatal hemorrhages, fatal arrhythmias).
High-Risk NTI Drug List
Warfarin (Coumadin, Jantoven): Target INR 2.0–3.0 (2.5–3.5 for mechanical valves). Slight bioavailability shifts precipitate fatal intracerebral hemorrhage or ischemic stroke.
Levothyroxine (Synthroid, Levoxyl, Unithroid): Microgram dosing. Small bioinequivalences alter serum TSH, causing thyrotoxic cardiac arrhythmias or severe hypothyroidism.
Digoxin (Lanoxin): Therapeutic serum range 0.5–0.9 ng/mL (heart failure) or 0.8–2.0 ng/mL (atrial fibrillation). Toxicity causes fatal ventricular arrhythmias and heart block.
Carbamazepine (Tegretol, Carbatrol): Therapeutic range 4–12 mcg/mL. Subtherapeutic levels cause breakthrough status epilepticus; toxicity causes aplastic anemia, ataxia, and Stevens-Johnson Syndrome (SJS).
Lithium (Lithobid, Eskalith): Therapeutic range 0.6–1.2 mEq/L. Toxicity occurs at levels >1.5 mEq/L (tremor, seizures, acute renal failure, coma).
Theophylline (Theo-24, Theochron): Therapeutic range 5–15 mcg/mL. Toxicity causes intractable seizures and tachyarrhythmias.
Phenytoin (Dilantin, Phenytek): Therapeutic range 10–20 mcg/mL. Exhibits non-linear Michaelis-Menten kinetics where a minor dose/bioavailability increase leads to exponential serum accumulation and cerebellar toxicity.
Tacrolimus (Prograf) & Cyclosporine (Sandimmune, Neoral): Critical immunosuppressants. Sandimmune (non-modified) and Neoral (microemulsion-modified) are NOT bioequivalent and must NEVER be interchanged without prescriber titration.
Warning
NTI Verification Standard: Many state pharmacy boards require the pharmacy to maintain patients on the same manufacturer for NTI refills. If a manufacturer switch is unavoidable due to drug shortages, the technician must alert the pharmacist so that prescriber notification and serum drug level re-monitoring can occur.
6. Dispense as Written (DAW) Codes Matrix
The National Council for Prescription Drug Programs (NCPDP) establishes standardized Dispense as Written (DAW) codes. Technicians must verify that the electronic billing code perfectly mirrors the legal instructions written on the original prescription and the physical product selected.
DAW Code NCPDP Description Operational Meaning & Verification Action
DAW 0 No Product Selection Indicated Prescriber permits generic substitution; pharmacy dispenses generic AB-rated product. Standard default code for uninhibited dispensing.
DAW 1 Substitution Not Allowed by Prescriber Prescriber explicitly requests brand-name product as medically necessary. Hardcopy or e-prescription must state 'Brand Medically Necessary' or 'Dispense as Written' in prescriber's handwriting or certified e-script field. Mandatory brand dispensing.
DAW 2 Substitution Allowed - Patient Requested Product Dispensed Prescriber permits generic substitution, but patient specifically demands the brand-name product. Patient typically pays the higher brand co-pay plus the price differential. Verify patient's explicit consent for out-of-pocket costs.
DAW 3 Substitution Allowed - Pharmacist Selected Product Dispensed Prescriber permits generic, but pharmacist exercises professional judgment to dispense brand (e.g., specific clinical brand available, private label brand). Rarely utilized.
DAW 4 Substitution Allowed - Generic Drug Not in Stock Prescriber permits generic, but generic formulation is temporarily out of stock. Pharmacy dispenses brand-name medication but bills at the generic co-pay tier according to plan rules.
DAW 5 Substitution Allowed - Brand Drug Dispensed as a Generic Pharmacy dispenses the brand-name medication from inventory but bills and prices it as a generic equivalent (often due to bulk purchasing discounts where brand is cheaper than generic).
DAW 6 Override Billing override code utilized in specialized adjudication circumstances mandated by specific third-party payers.
DAW 7 Substitution Not Allowed - Brand Drug Mandated by Law State statute or board regulation mandates the brand-name product be dispensed (e.g., specific state NTI formulary mandates where generic substitution is statutorily restricted).
DAW 8 Substitution Allowed - Generic Drug Not Available in Marketplace Generic version is FDA-approved but not commercially available in the national supply chain (e.g., manufacturer stop-ship, active drug shortage). Brand dispensed.
DAW 9 Other / Plan-Mandated Brand Third-party insurance plan mandates dispensing the brand-name product over the generic because the payer has negotiated a favorable manufacturer rebate (e.g., insulin pens, hepatitis C regimens).